TNFRSF4 and neoplasm: Additionally, Farazi et al. reported that chronic CR preserved antigen-specific CD4+ T cell priming and induced a significant survival benefit when combined with anti-OX40 (CD134) immunotherapy in aged tumor-bearing mice (23).